The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...

That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the first medicine the Carlsbad, ...

Shortly after unveiling a $400 million upgrade at its campus in Hillerød, Denmark, Novo Nordisk is reinforcing its commitment ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...